Physician profile
Abdullah Malas
NPI 1801328083
$6,144.35
in general payments reported to CMS, 2019-2025
36 companies · $5,154 in 2025
The $5,154 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2021: $103 · 2022: $25.01 · 2023: $290 · 2024: $431 · 2025: $5,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Food and Beverage: $1,825 · Travel and Lodging: $1,399 · Consulting Fee: $650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Food and Beverage | $1,824.99 |
| Travel and Lodging | $1,399.21 |
| Consulting Fee | $650.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avyxa Pharma, LLC | $3,820.08 | 2025 | |
| Daiichi Sankyo INC. | $700.97 | 2025 | Vanflyta, Enhertu |
| Novartis Pharmaceuticals Corporation | $201.59 | 2024-2025 | |
| Abbott Laboratories | $141.74 | 2019 | |
| Adc Therapeutics America, INC. | $103.40 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $100.02 | 2023-2025 | Enhertu, Lynparza, Calquence |
| Pfizer INC. | $69.62 | 2023-2025 | |
| Agios Pharmaceuticals, INC. | $61.12 | 2024-2025 | Pyrukynd |
| Jazz Pharmaceuticals INC. | $58.31 | 2024-2025 | |
| Abbvie INC. | $56.85 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.59 | 2024 | Ninlaro, Alunbrig |
| Janssen Biotech, INC. | $55.84 | 2023-2025 | Erleada, Darzalex, Imbruvica |
| Sumitomo Pharma America, INC. | $53.80 | 2024-2025 | Orgovyx |
| Gilead Sciences, INC. | $47.92 | 2025 | Trodelvy |
| Eisai INC. | $46.14 | 2023-2025 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdullah Malas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.